TECHNOPHAGE, a Portuguese company specializing in GMP phage development and PHAXIAM Therapeutics, a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, announce today its intent to establish a strategic collaboration. This strategic partnership aims to provide physicians with access to a comprehensive GMP phage portfolio, enabling the implementation of Individualized Phages Therapies (IPT) through shared capabilities.
This collaboration seeks to deliver a faster and more effective response to the growing challenge of severe resistant infections. By combining PHAXIAM’s GMP phages portfolio and advanced diagnostic capabilities, including its phagogram-based approach, with TECHNOPHAGE´s GMP phages portfolio and GMP manufacturing expertise, the partnership aims to drive innovation and accelerate access to IPT.
The combined GMP phage portfolios will significantly enhance the number and diversity of GMP phages available for IPT. The partnership aims to achieve a collection of 25 GMP phages by the end of 2025 and 35-40 GMP phages by the end of 2026. This expanded portfolio will target at least seven of the most critical pathogens: Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, in addition to two other key pathogen targets. Together, these seven pathogens account for approximately 70% of the most prevalent severe resistant infections.
To access the full text, please refer to the Press Release.